Erythromycin For Pneumonia Outpatients
Agency for Healthcare Research and Quality (AHRQ)Using the antibiotic erythromycin for treating community-acquired pneumonia (CAP) in most outpatients aged 60 and under significantly reduces treatment costs compared with the use of other antibiotics and has no adverse effect on medical outcomes. This finding is from an AHCPR-funded study which provides the first objective data to compare the clinical effectiveness and costs of antibiotic therapy with clinical guidelines for community-acquired pneumonia.